Fermenta Biotech grants 3,95,400 ESOPs, seeks NSE listing
Fermenta Biotech Limited granted 3,95,400 stock options to eligible employees under FBL ESOP 2025 at Rs. 83.67 per option and approved the re-appointment of Ms. Rajeshwari Datla as Non-executive Director. The Board also applied for a direct listing on the NSE and approved a private placement by its subsidiary, Fermenta Environment Solutions Private Limited.
*this image is generated using AI for illustrative purposes only.
Fermenta Biotech Limited granted 3,95,400 stock options to eligible employees under its Employee Stock Option Scheme 2025 (FBL ESOP 2025) at an exercise price of Rs. 83.67 per option. The Board of Directors also approved the re-appointment of Ms. Rajeshwari Datla as a Non-executive Director, subject to shareholder approval at the ensuing 74th Annual General Meeting (AGM). These decisions were taken during the Board meeting held on May 26, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The Compensation Committee approved the grant of options, which are convertible into 3,95,400 equity shares of Rs. 5 each. The options will have a vesting period of a minimum of one year from the date of grant, and the exercise period for vested options will be a maximum of three years. The scheme complies with the SEBI (Share Based Employee Benefits) Regulations, 2021.
Ms. Rajeshwari Datla, who has been a non-executive director since 2005, is liable to retire by rotation at the upcoming AGM. The Board also approved her continuation as a Non-Executive Director, noting she has attained the age of 76. This continuation is subject to the approval of the company's members and complies with regulation 17(1A) of the Listing Regulations. Ms. Datla is the mother of Ms. Anupama Datla Desai, Executive Director, and Mr. Krishna Datla, Executive-Vice Chairman.
In a strategic move, the Board granted approval to apply for the listing and trading of the company's equity shares on the National Stock Exchange of India Limited via a direct listing route. Furthermore, the Board gave in-principle approval to its wholly-owned subsidiary, Fermenta Environment Solutions Private Limited (FESPL), to consider a private placement of equity shares. Upon successful allotment, FESPL will cease to be a wholly-owned subsidiary. The Board also approved the implementation of an ESOP for FESPL's employees, including those of the holding company.
Key ESOP Details
| Particulars | Details |
|---|---|
| Options Granted | 3,95,400 |
| Exercise Price | Rs. 83.67 per option |
| Shares Covered | 3,95,400 equity shares of Rs. 5 each |
| Vesting Period | Minimum 1 year from date of grant |
| Exercise Period | Maximum 3 years from vesting date |
Historical Stock Returns for Fermenta Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +2.38% | +0.12% | -7.51% | -7.51% | -7.51% | -7.51% |
What is the expected timeline for the direct listing of equity shares on the National Stock Exchange?
How will the potential private placement in Fermenta Environment Solutions impact the holding company's consolidated financials?
What strategic rationale drives the decision to reduce stake in FESPL from wholly-owned to a subsidiary status?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
